Clinical Medicine; Translational Medical Research
- A Novel Approach of Defining Therapeutic Targets in an Orphan Disease: Formalin-fixed paraffin-embedded Tumor Tissue and Ascites-derived Cell Pellets as a Promising Source for RNA-Profiling in Mucinous Ovarian Cancer (2021)
Source of Funding: City of Vienna, Vienna Fund for Innovative Interdisciplinary Cancer Research
- Molecular Characterisation of Novel Therapeutic Targets in Mucinius Ovarian Cancer (2019)
Source of Funding: Medical Scientific Fund of the Mayor of the City of Vienna, Gynecologic Oncology
Coordinator of the collaborative project
- Mucinous Ovarian Cancer in the Era of Personalized Medicine: Definition of Novel Biomarkers Predictive of Therapy Response (2019)
Source of Funding: City of Vienna, City of Vienna Jubilee Fund
- Bartl, T. et al. 2023. Biomarkers for checkpoint inhibitor therapy in mucinous epithelial ovarian cancer. Int J Gynecol Cancer. 2023 Apr 24; ijgc-2023-004360. doi: 10.1136/ijgc-2023-004360.
- Bartl, T. et al. 2021. Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients. Biomolecules 2021, 11, 1700. doi: 10.3390/biom11111700.
- Bartl, T. et al., 2021. Tumor Growth Rate Estimates Are Independently Predictive of Therapy Response and Survival in Recurrent High-Grade Serous Ovarian Cancer Patients. Cancers, 13(5), p.1076. doi: 10.3390/cancers13051076
- Bartl, T. et al. 2021 ‘The systemic immune-inflammation index (SII) is an independent prognostic parameter of survival in patients with invasive vulvar cancer’, Journal of Gynecologic Oncology, 32(1). Available at: http://dx.doi.org/10.3802/jgo.2021.32.e1.
- Bartl T. et al, 2018. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2018 Nov;28(9):1664-1671. doi: 10.1097/IGC.0000000000001369.